BCR-ABL1 (Philadelphia chromosome) — Targeted Therapies, Trials & Pipeline
The BCR-ABL1 fusion oncogene from t(9;22) drives chronic myeloid leukemia and Ph+ ALL; quantified by RT-qPCR and targeted by sequential tyrosine kinase inhibitors, with the T315I gatekeeper mutation guiding later-line selection.